Keytruda's Current Price
Keytruda (pembrolizumab), Merck's blockbuster cancer immunotherapy, costs about $11,000 per 100 mg vial in the U.S. before discounts or insurance. A typical three-week dose for a 70 kg patient (200 mg) runs around $22,000-$25,000, depending on provider pricing and markups.[1][2] Annual treatment often exceeds $150,000-$200,000 for ongoing regimens.
No True Generics Yet—Why?
Keytruda has no approved generics or biosimilars in the U.S. as of 2024. It's a biologic monoclonal antibody, so only interchangeable biosimilars (not small-molecule generics) can compete, requiring FDA approval after patent expiry. Key patents, like U.S. Patent 8,952,137 for the PD-1 antibody composition, expire in 2028, with others extending to 2035 via pediatric exclusivity.[3] Merck reported $25 billion in 2023 Keytruda sales, fueling aggressive patent defenses.
Biosimilar Timeline and Potential Savings
First U.S. biosimilars could launch post-2028 if litigation clears. In Europe, where some patents expired earlier, Samsung Bioepis's Tukysa (pembrolizumab biosimilar) got approval in 2024 at 25-30% below Keytruda's list price.[4] Analysts project U.S. biosimilars could drop prices 20-40% initially (to $6,000-$8,000 per vial), with further erosion to 70-80% discounts over time, based on patterns from drugs like Humira.[5] Merck's patent thicket—over 100 filings—may delay this.[3]
| Scenario | Keytruda Price (per 100 mg vial) | Biosimilar Estimate | Savings Potential |
|----------|---------------------------------|---------------------|-------------------|
| U.S. Now | $11,000 | N/A | - |
| Europe 2024 | $11,000 | $7,500-$8,000 | 25-30% |
| U.S. Post-2028 | $11,000 | $6,000-$9,000 | 20-40% initial |
| U.S. Long-term | $11,000 | $2,000-$3,000 | 70-80% |
What Patients Pay After Discounts
List prices ignore rebates: Medicare patients face $0 copays via Merck's assistance post-$16,800 out-of-pocket cap (2024). Commercial insurance nets ~$4,000-$6,000 per dose after 50%+ rebates. Uninsured access programs cap costs at $5,000/month.[2] Biosimilars would still lower insurer and net prices significantly.
How Keytruda Stacks Up Against Cancer Drug Alternatives
Compared to small-molecule generics like generic imatinib (Gleevec) at $20-$50/month vs. original $8,000, savings hit 99% post-patent. Keytruda's peers:
- Opdivo (nivolumab, Bristol Myers): Similar $11,000/vial, biosimilars eyed for 2026.
- Tecentriq (atezolizumab): $12,000+/dose, patents to 2030s.
Biosimilars for these could benchmark Keytruda's future drop.[6]
[1]: Drugs.com - Keytruda Pricing
[2]: GoodRx - Keytruda Costs
[3]: DrugPatentWatch.com - Keytruda Patents
[4]: EMA - Tukysa Approval
[5]: IQVIA Biosimilar Report 2024
[6]: FiercePharma - Immunotherapy Pricing